Shanghai Kaibao Pharmaceutical Tangible Net Worth Ratio
Shanghai Kaibao Pharmaceutical tangible net worth ratio. Shanghai Kaibao Pharmaceutical (300039) has a Tangible Net Worth Ratio of 96.2% as of June 2026. This metric is calculated by deducting intangible assets (CN¥160.97 Million) from net assets (CN¥4.29 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 300039 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Shanghai Kaibao Pharmaceutical (2006–2025)
Tangible net worth ratio of Shanghai Kaibao Pharmaceutical from 2006 to 2025. This chart shows how Shanghai Kaibao Pharmaceutical's Tangible Net Worth Ratio has changed across 20 annual periods from 2006 to 2025. As of June 2026, the ratio stands at 96.2%, reflecting net assets of CN¥4.29 Billion with intangible assets of CN¥160.97 Million CNY. See Shanghai Kaibao Pharmaceutical (300039) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shanghai Kaibao Pharmaceutical Tangible Net Worth Ratio by Year (2006–2025)
Shanghai Kaibao Pharmaceutical tangible net worth ratio by year from 2006 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Shanghai Kaibao Pharmaceutical from 2006 to 2025, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Shanghai Kaibao Pharmaceutical market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.3% | CN¥4.42 Billion | CN¥163.57 Million | CN¥4.78 Billion | ▲ +0.4 pp |
| 2024 | 95.9% | CN¥4.10 Billion | CN¥168.80 Million | CN¥4.52 Billion | ▼ -3.0 pp |
| 2023 | 98.9% | CN¥4.03 Billion | CN¥45.11 Million | CN¥4.58 Billion | ▲ +0.1 pp |
| 2022 | 98.8% | CN¥3.76 Billion | CN¥44.23 Million | CN¥4.26 Billion | ▲ +0.2 pp |
| 2021 | 98.6% | CN¥3.04 Billion | CN¥42.90 Million | CN¥3.36 Billion | ▲ +0.3 pp |
| 2020 | 98.2% | CN¥2.58 Billion | CN¥45.26 Million | CN¥2.88 Billion | ▼ -0.1 pp |
| 2019 | 98.4% | CN¥2.57 Billion | CN¥41.33 Million | CN¥2.84 Billion | ▲ +0.1 pp |
| 2018 | 98.3% | CN¥2.49 Billion | CN¥42.12 Million | CN¥2.75 Billion | ▲ +0.2 pp |
| 2017 | 98.2% | CN¥2.37 Billion | CN¥43.75 Million | CN¥2.68 Billion | ▲ +0.2 pp |
| 2016 | 97.9% | CN¥2.20 Billion | CN¥45.38 Million | CN¥2.53 Billion | ▲ +0.3 pp |
| 2015 | 97.7% | CN¥2.01 Billion | CN¥46.79 Million | CN¥2.43 Billion | ▲ +0.2 pp |
| 2014 | 97.5% | CN¥1.88 Billion | CN¥47.12 Million | CN¥2.12 Billion | ▲ +0.1 pp |
| 2013 | 97.4% | CN¥1.61 Billion | CN¥42.30 Million | CN¥1.77 Billion | ▼ -0.8 pp |
| 2012 | 98.2% | CN¥1.42 Billion | CN¥25.86 Million | CN¥1.56 Billion | ▲ +0.2 pp |
| 2011 | 98.0% | CN¥1.33 Billion | CN¥26.48 Million | CN¥1.45 Billion | ▲ +0.2 pp |
| 2010 | 97.8% | CN¥1.24 Billion | CN¥27.12 Million | CN¥1.37 Billion | ▲ +0.2 pp |
| 2009 | 97.6% | CN¥1.15 Billion | CN¥27.80 Million | CN¥1.35 Billion | ▲ +0.2 pp |
| 2008 | 97.4% | CN¥126.92 Million | CN¥3.32 Million | CN¥229.88 Million | ▼ -1.4 pp |
| 2007 | 98.7% | CN¥76.96 Million | CN¥965.65K | CN¥161.61 Million | ▲ +2.3 pp |
| 2006 | 96.4% | CN¥37.24 Million | CN¥1.32 Million | CN¥109.03 Million | — |